-
Takeda's "Iatibant Acetate Injection" is about to be approved
Time of Update: 2021-04-27
However, in December 2020, Takeda's Ranarizumab was approved for marketing to prevent the onset of angioedema in HAE patients 12 years of age and older.
Today, Takeda's "Iatibant Acetate Injection" listing application has entered the administrative approval stage, which means that this type of patient may usher in the first acute treatment drug.
-
Renfu Medicine: Mifepristone tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
, a subsidiary of the company, received the "Drug Supplementary Application Approval Notice" from the State Food and Drug Administration on mifepristone tablets (notice Book number: 2020B05143), the drug passed the generic drug quality and efficacy consistency evaluation.
-
Hisun Pharmaceutical: Epirubicin Hydrochloride for Injection passed the consistency evaluation of generic drugs
Time of Update: 2021-04-27
On March 23, Hisun Pharmaceutical announced that the company's epirubicin hydrochloride for injection has passed the quality and efficacy consistency evaluation of generic drugs.
On May 5, 2019, the State Food and Drug Administration accepted the company's application for the consistency evaluation of epirubicin hydrochloride for injection.
-
Fuan Pharmaceutical: Cefminox sodium for injection passed the consistency evaluation
Time of Update: 2021-04-27
, has recently received a supplementary drug application approval notice issued by the National Medical Products Administration, and its product Cefminox sodium for injection has passed The quality and efficacy consistency evaluation of generic drugs.
Cefminox sodium for injection is an anti-infective drug.
-
Sanming Medical Reform makes headlines again!
Time of Update: 2021-04-27
MD, director of the annual salary of up to 60 Wan While drastically reducing the prices of medicines and consumables, Sanming has implemented a reform of changing cages for birds, greatly increasing medical service fees, and implementing an annual salary system for doctors.
-
Dongyang Sunshine's "Entacapone Film" Approved for Listing
Time of Update: 2021-04-27
Recently, the official website of the State Food and Drug Administration showed that the entacapone tablets declared by Dongyang Sunshine according to registration classification 4 have been approved for marketing by NMPA (approval number: National Medicine Standard H20213207).
-
Renhe Pharmaceuticals Entecavir Tablets Obtained Drug Registration Certificate
Time of Update: 2021-04-27
Entecavir tablets product indications are: This product is suitable for the treatment of chronic adult hepatitis B (including compensation and Patients with liver disease in decompensated stage).
-
Central Document: Four New Changes in the Development of Village Clinics
Time of Update: 2021-04-27
Rural revitalization cannot do without the support of rural medical and health services, and the improvement of rural doctors' medical and health services is inseparable The promotion of rural doctors' talent team is inseparable from the expansion and development of village-level medical institutions.
-
Ganli Pharmaceutical's GZR18 clinical application was accepted by NMPA
Time of Update: 2021-04-27
For obesity and overweight indications, currently, no GLP-1 receptor agonist drug that is injected once a week has been approved for obesity and overweight treatment globally.
-
Pfizer said an oral new crown treatment drug has entered clinical trials
Time of Update: 2021-04-27
On March 24th, 23rd local time in the United States, the pharmaceutical company Pfizer announced on its official website that the oral new crown treatment drug PF-07321332 has entered the phase 1b clinical trial phase.
This is the world's first oral new crown treatment drug to enter clinical trials.
-
Qilu's two Class 1 new drugs are coming raging and target the 100 billion market
Time of Update: 2021-04-27
According to data from Minaiwang, since 2021, Qilu Pharmaceuticals has already approved two Class 2 improved new drugs for marketing, and three innovative drugs have been applied for clinical trials, of which two have been approved for clinical use.
-
Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation
Time of Update: 2021-04-27
("Shandong Luoxin") had recently received the approval and issue of Ogilvy for Injection from the National Medical Products Administration.
The omeprazole sodium for injection developed by Shandong Luoxin was first approved for marketing in 2005.
-
Ripretinib introduced by Zai Lab is approved for fourth-line treatment of gastrointestinal stromal tumors soon
Time of Update: 2021-04-27
In May 2020, the drug was approved by the FDA for the treatment of advanced gastrointestinal stromal tumors (GIST) who have been treated with three or more lysine kinase inhibitors (TKI) including imatinib ) An adult patient, with the trade name Qinlock, became the first approved fourth-line treatment for GIST.
-
CCTV Exposure: The price of Chinese medicine has risen again
Time of Update: 2021-04-27
cn/" target="_blank"> and regulations In addition, the publication of higher standards of the new version of the Pharmacopoeia is also conducive to the development of medicinal materials e-commerce.
-
"National Drug Sampling Inspection Annual Report (2020)" released
Time of Update: 2021-04-27
Medical Network, March 24 News On March 23, the website of China Food and Drug Control Institute released the "National Drug Sampling Inspection Annual Report (2020)" (hereinafter referred to as the
-
Luye Pharma's Class 1 new drug Ansufaxine Hydrochloride Sustained-Release Tablets reached the preset end point in Phase III clinical trials
Time of Update: 2021-04-27
The China Phase III clinical trial of LY03005 is a multi-center, randomized, double-blind, placebo-controlled study to verify the effectiveness and safety of LY03005 in the treatment of depression.
-
Novo Nordisk's high-dose semaglutide treatment application for diabetes is rejected by the FDA
Time of Update: 2021-04-27
0 mg once a week for treatment 2 Application for label extension for type-diabetes.
Although more information needs to be included in the resubmission, Novo Nordisk stated that the company believes that the completed clinical trial projects are sufficient to support semaglutide's label extension application.
-
First-line treatment for advanced esophageal cancer: Can the domestic PD-1 eye-catching K drug sit on the top spot?
Time of Update: 2021-04-27
Following the three major clinical studies of Keynote-181, ATTRACTION-3, and ESCORT to establish the role and status of PD-1 monoclonal antibody in the second-line treatment of advanced esophageal squamous cell carcinoma, the release of the Keynote-590 study at the European Society of Medical Oncology (ESMO) in 2020 It directly brings the combination of immunotherapy and chemotherapy into the first-line treatment of advanced esophageal cancer.
-
The heads of the Ministry of Justice, the State Administration of Market Supervision, and the Food and Drug Administration answer questions from reporters on the Regulations on the Supervision and Administration of Medical Devices
Time of Update: 2021-04-27
Question: In 2017, the Central Office and the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging Innovation in Drugs and Medical Devices", proposing to promote the full implementation of the marketing authorization holder system.
-
Chengdu Better Pharmaceutical's Ampicillin Sodium for Injection has been successfully evaluated
Time of Update: 2021-04-27
On March 22, the official website of the State Food and Drug Administration showed that Chengdu Better Pharmaceutical's Ampicillin Sodium for injection successfully passed the evaluation, and it was the first in China; in addition, the company recently imitated the 4 types of dabigatran etexilate capsules.
